Lacosamid Aaa-Pharma (Lacosamide)

Lacosamide is an antiepileptic that acts on voltage‑gated sodium channels to control focal seizure activity.

• Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy.
• Adjunctive therapy in epilepsy: used alongside other antiepileptics to improve overall seizure control.
• Focal epilepsy: provides additional seizure reduction for patients not adequately controlled by monotherapy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilises hyper‑excitable neuronal membranes and diminishes repetitive neuronal firing. By selectively targeting the slow inactivation phase, it reduces the propagation of epileptiform activity without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Fatigue: feeling unusually tired.
• Vision changes: blurred vision or double vision.

Serious or Rare Side Effects

• Suicidal thoughts: emergence of depressive or suicidal ideation.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Cardiac arrhythmias: including PR‑interval prolongation.
• Liver enzyme elevations: abnormal hepatic function tests.
• Allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution in patients with liver disease.
• Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the patient.
• Concomitant CNS depressants: may increase sedation; observe for enhanced drowsiness.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

• Carbamazepine: may lower lacosamide plasma concentrations.
• Phenytoin: can reduce lacosamide exposure.
• Strong CYP3A4 inducers (e.g., rifampin): may decrease therapeutic effect.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines): may increase sedation.
• Anticoagulants (e.g., warfarin): may alter INR values.
• Alcohol: can enhance dizziness and coordination problems.